Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411412 | 1.00 | LTA4H (0.58) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2289325 | 0.99 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL16919769 | 0.99 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2293014 | 0.99 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2289337 | 0.99 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2293011 | 0.99 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL23425420 | 0.94 | SIRT2 (0.55) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL30541877 | 0.94 | LTA4H (0.53) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL10459445 | 0.93 | MMP2 (0.58) | LTA4HMMP2ECE1CTSLANPEP | |
| SCHEMBL10459444 | 0.93 | MMP2 (0.58) | LTA4HMMP2ECE1CTSLANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630848-B1 | PROCESS FOR GALNAC OLIGONUCLEOTIDE CONJUGATES | HOFFMANN LA ROCHE (CH) | 2023-10-04 | — | — | EP | disclosed |
| CN-110621700-B | Method for GalNAc oligonucleotide conjugates | 豪夫迈·罗氏有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11021503-B2 | Process for GalNAc oligonucleotide conjugates | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3377510-B1 | GALNAC CLUSTER PHOSPHORAMIDITE | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| US-10590156-B2 | Galnac cluster phosphoramidite | HOFFMANN-LA ROCHE INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019145543-A1 | PROCESS FOR THE PREPARATION OF GALNAC OLIGONUCLEOTIDE CONJUGATES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-01 | — | — | WO | disclosed |
| EP-3331892-B1 | PROCESSES FOR THE PREPARATION OF GALNAC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011104169-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021503-B2 | Process for GalNAc oligonucleotide conjugates | CSGALNACT1, ALG1, ALG8 | LTA4H 2291/4885MMP2 2821/4885ECE1 4165/4885 |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | LTA4H 4116/4885MMP2 3533/4885ECE1 3585/4885 |
| US-10590156-B2 | Galnac cluster phosphoramidite | B4GALT1, FUT5, FUT6 | LTA4H 1978/4885MMP2 3788/4885ECE1 3303/4885 |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.